Venkatraman Radhakrishnan: Reduction in chemo dose intensity by 25% and adding Rituximab improves survival in pediatric high-grade B Non-Hodgkins Lymphoma in resource-limited settings.

Venkatraman Radhakrishnan, Consultant, Medical and Pediatric Oncology at Cancer Institute Adyar, recently shared the following insight on X/Twitter:

“Reduction in chemo dose intensity by 25% and adding Rituximab improves survival in pediatric high-grade B Non-Hodgkins Lymphoma in resource-limited settings.

Outcomes are comparable to high-income countries. A 25% improvement in survival compared to the past.

-Malnutrition and MDR Gram-negative bacteria associated with increased mortality in pediatric B NHL in LMICs.
-A less dose-intense protocol reduces toxicity and treatment-related mortality and allows for giving chemo on time thereby reducing relapses.
-Rituximab compensates for the reduction in dose intensity.”

For the article click here.
Source: Vnkatraman Radhakrishnan/Twitter